Home / Business and Economy / Transgene Biotek's Q3 2025 Earnings Plummet, Signaling Ongoing Challenges
Transgene Biotek's Q3 2025 Earnings Plummet, Signaling Ongoing Challenges
15 Nov, 2025
Summary
- Sales declined 16.67% to Rs 0.05 crore in Q3 2025
- Net Loss widened to Rs 0.39 crore in Q3 2025 from Rs 0.07 crore in Q3 2024
- Ongoing financial struggles for the company
In the third quarter of 2025, Transgene Biotek faced significant financial challenges, as evidenced by a 16.67% decline in sales to Rs 0.05 crore and a widening net loss of Rs 0.39 crore, up from Rs 0.07 crore in the same period the previous year.
The company's sales have been on a downward trajectory, dropping from Rs 0.06 crore in the third quarter of 2024 to just Rs 0.05 crore in the most recent quarter. This sales decline, coupled with the growing net loss, suggests that Transgene Biotek is struggling to maintain its financial footing and profitability.
The company's financial performance in the third quarter of 2025 indicates that it is facing ongoing challenges in its operations and market positioning. With sales declining and losses mounting, Transgene Biotek will need to take decisive action to address these issues and chart a path towards a more sustainable future.
